AIOS, a healthcare AI-native infrastructure company, has reached $350 million in annual recurring revenue (ARR), up from $9 million in Q2 2025, demonstrating exponential growth. The company targets low-cost, scalable, and automated healthcare solutions, with a focus on obesity treatment through brands like Bolt Pharmacy and Fella Health, and projects serving 100 million patients globally by 2035.
AIOS's growth is propelled by its focus on specific healthcare niches, leveraging AI to create a scalable infrastructure that can be extended across various healthcare segments. The company's strategy of starting with high-impact categories and expanding its infrastructure is driving rapid adoption, supported by the founder's strong track record in AI applications.
Legacy healthcare providers have been slow to adopt AI, due to the complex regulatory environment and entrenched legacy systems. AIOS capitalizes on this gap by offering a modern, AI-native solution that can integrate with existing systems and provide immediate value, thereby disrupting the status quo.
"AIOS's rapid growth signifies a paradigm shift in healthcare towards AI-driven solutions, setting a precedent for the potential of AI in transforming traditional industries."